Biochemical mechanism of HIV-1 resistance to rilpivirine.
about
Current perspectives on HIV-1 antiretroviral drug resistanceA mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptaseStructure of a Dihydroxycoumarin Active-Site Inhibitor in Complex with the RNase H Domain of HIV-1 Reverse Transcriptase and Structure–Activity Analysis of Inhibitor AnalogsInvestigating the mutation resistance of nonnucleoside inhibitors of HIV-RT using multiple microsecond atomistic simulations.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanismsFactors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries.Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants.Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitorsMass spectrometric analysis of protein-ligand interactions.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants.Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor.Docking Field-based QSAR and pharmacophore studies on the substituted pyrimidine derivatives targeting HIV-1 reverse transcriptase.A 2-hydroxyisoquinoline-1,3-dione active site RNase H inhibitor binds in multiple modes to HIV-1 reverse transcriptase.Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa.Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.Real-life rilpivirine resistance and potential emergence of an E138A-positive HIV strain in north-eastern France.Effects of the protonation state in the interaction of an HIV-1 reverse transcriptase (RT) amino acid, Lys101, and a non nucleoside RT inhibitor, GW420867X.Computational development of rubromycin-based lead compounds for HIV-1 reverse transcriptase inhibition.The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa.Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse SubtypesExploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action
P2860
Q26852626-4C6D0C87-1081-4664-874C-6FE3CC472802Q27683249-9D59C358-EB2D-47E5-A078-C1ADC8ECB4C7Q27683831-FB24A117-AD14-42DA-8708-2437BA7AEF81Q30456752-3E99A05B-4EF0-455B-A48B-8DC2D132A669Q33900459-088060B6-B8DE-4863-B25A-E991B9C8E12CQ34107343-8207E38A-3049-4DC8-B612-700CBF84FB3CQ36455357-79762B7E-8360-4D2C-866C-C76C082E9EBAQ36583683-B414502D-1C3C-4D21-BAEE-37625072696AQ36969977-6DB05077-5D02-4B0B-A924-76B2E596A136Q37263541-82B2A113-310D-4B65-BBEF-CC9B85A6039CQ37296199-8B9F0D82-CBF8-481D-A21C-619AEBE4116BQ37547275-CAB197A5-B503-4E3F-9CE9-79C66A21FF05Q37643598-016A8C94-C31E-4568-8652-020D95685E11Q38620336-741DE5DF-503F-4AB7-BC97-A1C100F12EBFQ38856111-04E56020-3F57-4BC8-8423-DB7A90C7F9D4Q40080043-AB61BF36-4C72-478E-A3CD-A0689DBCCB4DQ40100646-8A2905E6-0491-441D-A83F-9847F5DBA2A3Q40473808-37AB1FC1-37AB-42EF-8EE3-2472D37819BBQ40978625-A7DA788E-BBBF-4664-AB30-101FD791D31DQ42207342-D8F53759-7417-4744-B84D-9BB479FC3E7FQ42209969-36C85D47-5185-4188-B3C4-F427528B4518Q42739347-6B0923A3-28AF-4098-8BFF-E8AB3580E751Q47549305-D383CA0D-DBCA-4E23-A2F7-77460509BFB6Q52352259-62134005-AD41-4A05-9184-5672695E56AAQ56926444-E6F7A676-1AFA-43AC-88E1-A4197E7BC2FAQ58580888-149444B4-F6D2-406E-8952-A3A1534EA082
P2860
Biochemical mechanism of HIV-1 resistance to rilpivirine.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Biochemical mechanism of HIV-1 resistance to rilpivirine.
@ast
Biochemical mechanism of HIV-1 resistance to rilpivirine.
@en
type
label
Biochemical mechanism of HIV-1 resistance to rilpivirine.
@ast
Biochemical mechanism of HIV-1 resistance to rilpivirine.
@en
prefLabel
Biochemical mechanism of HIV-1 resistance to rilpivirine.
@ast
Biochemical mechanism of HIV-1 resistance to rilpivirine.
@en
P2093
P2860
P356
P1476
Biochemical mechanism of HIV-1 resistance to rilpivirine.
@en
P2093
Ariel N Hagedorn
Atsuko Hachiya
Bechan Sharma
Bruno Marchand
Devendra K Rai
Eleftherios Michailidis
Emily M Ryan
Hong-Tao Xu
Kamalendra Singh
Kayla B Matzek
P2860
P304
38110-38123
P356
10.1074/JBC.M112.398180
P407
P577
2012-09-06T00:00:00Z